RAD51D and ovarian cancer: Apart from BRCA1/2, recent studies have revealed that the somatic reversion mutations of the core HR genes, RAD51C and RAD51D, might be mechanisms of acquired resistance to the PARPis, rucaparib, in ovarian cancers [9].